Aspira Women S Health Inc Revenue Growth Rates (AWHL), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Aspira Women s Health inc   (AWHL)
 

AWHL's Revenue Growth by Quarter and Year

Aspira Women S Health Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

AWHL Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 0.02
1st Quarter March 5.08
FY 5.10

AWHLs Annual Revenue
Aspira Women S Health Inc 's Revenue in the fiscal year 2025 $ 8.92 millions
Aspira Women S Health Inc 's Revenue in the fiscal year 2024 $ 8.48 millions
Aspira Women S Health Inc 's Revenue in the fiscal year 2023 $ 9.15 millions
Aspira Women S Health Inc 's Revenue in the fiscal year 2022 $ 8.18 millions
Aspira Women S Health Inc 's Revenue in the fiscal year 2021 $ 6.81 millions




AWHL Revenue second quarter 2026 Y/Y Growth Comment
Aspira Women S Health Inc reported drop in Revenue in the second quarter 2026 by -99.04% to $ 0.02 millions, from the same quarter in 2025.
Despite modest results in the second quarter 2026, contraction in Aspira Women S Health Inc 's Revenue appears to be smaller than Company's recent average decline.

Looking into second quarter 2026 results within In Vitro & In Vivo Diagnostic Substances industry 9 other companies have achieved higher Revenue growth. While Aspira Women S Health Inc ' s Revenue meltdown of -99.04% ranks overall at the positon no. 2911 in the second quarter 2026.


AWHL Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 386.89 % -42.72 % -0.93 %
3rd Quarter September - - 9.46 % 7.25 %
2nd Quarter June -99.04 % -26.45 % -2.81 % 20.29 %
1st Quarter March 58.75 % 33.33 % 3.45 % 22.75 %
FY   - 5.31 % -7.53 % -

Financial Statements
Aspira Women S Health Inc 's second quarter 2026 Revenue $ 0.02 millions AWHL's Income Statement
Aspira Women S Health Inc 's second quarter 2025 Revenue $ 1.78 millions Quarterly AWHL's Income Statement


AWHL Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - - -49.79 % -4.05 %
3rd Quarter September - - 0.41 % -10.84 %
2nd Quarter June -99.67 % -44.38 % 0.83 % 7.33 %
1st Quarter March -14.48 % 162.3 % 12.68 % 7.91 %
FY (Year on Year)   - 5.31 % -7.53 % -


Back to AWHL Growth rate Comparisons >> Back to AWHL Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #10
Healthcare Sector #402
Overall #2911

Revenue Y/Y Growth Statistics
High Average Low
65.4 % -2397.31 % -28405.65 %
(Mar 31 2017)   (Sep 30 2021)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #10
Healthcare Sector #402
Overall #2911
Revenue Y/Y Growth Statistics
High Average Low
65.4 % -2397.31 % -28405.65 %
(Mar 31 2017)   (Sep 30 2021)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Aspira Women S Health Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
385.76 % 15.11 % -100 %
(Dec 31 2014)  


AWHL's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2026 Aspira Women S Health Inc disclosed fall in Revenue from the first quarter by -99.67% to $ 0.02 millions, from $ 5.08 millions achived in the previous reporting period.

But that's not important problem, as Aspira Women S Health Inc 's Revenue generally seem to plunge in this quarter.

Within In Vitro & In Vivo Diagnostic Substances industry 13 other companies have achieved higher Revenue quarter on quarter growth. While Aspira Women S Health Inc 's Revenue growth quarter on quarter, overall rank is 3828.


Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #14
Healthcare Sector #587
Overall #3828
Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #14
Healthcare Sector #587
Overall #3828
Revenue Q/Q Growth Statistics
High Average Low
385.76 % 15.11 % -100 %
(Dec 31 2014)  


AWHL's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2026 Aspira Women S Health Inc disclosed fall in Revenue from the first quarter by -99.67% to $ 0.02 millions, from $ 5.08 millions achived in the previous reporting period.

But that's not important problem, as Aspira Women S Health Inc 's Revenue generally seem to plunge in this quarter.

Within In Vitro & In Vivo Diagnostic Substances industry 13 other companies have achieved higher Revenue quarter on quarter growth. While Aspira Women S Health Inc 's Revenue growth quarter on quarter, overall rank is 3828.


Aspira Women S Health Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 9.03 $ 10.79 $ 8.92 $ 4.20 $ 8.63
Y / Y Revenue Growth (TTM) 4.57 % 16.36 % 5.14 % -55.26 % -5.87 %
Year on Year Revenue Growth Overall Ranking # 2880 # 2064 # 2655 # 2013 # 1593
Seqeuential Revenue Change (TTM) -16.34 % 21.05 % 112.31 % -51.37 % -6.91 %
Seq. Revenue Growth (TTM) Overall Ranking # 2916 # 1375 # 2728 # 2005 # 1776


Cumulative Revenue growth Comment
Assuming the Aspira Women S Health Inc 's fiscal year would have ended in Jun 30 2026, Aspira Women S Health Inc would have reprted above average annual Revenue improvement of 4.57% year on year, of $ 9 millions.
This marks a slow-down of the companys growth trends and from the 16.36% rise in Mar 31 2026.

In the Healthcare sector 397 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2064 to 2880.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 10
Healthcare Sector # 398
Overall # 2880

Revenue TTM Y/Y Growth Statistics
High Average Low
65.4 %
 -2397.31 %
-28405.65 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 10
Sector # 402
S&P 500 # 2916
Cumulative Revenue growth Comment
Assuming the Aspira Women S Health Inc 's fiscal year would have ended in Jun 30 2026, Aspira Women S Health Inc would have reprted above average annual Revenue improvement of 4.57% year on year, of $ 9 millions.
This marks a slow-down of the companys growth trends and from the 16.36% rise in Mar 31 2026.

In the Healthcare sector 397 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2064 to 2880.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 10
Healthcare Sector # 398
Overall # 2880

Revenue TTM Y/Y Growth Statistics
High Average Low
65.4 %
-2397.31 %
-28405.65 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 10
Sector # 402
S&P 500 # 2916




Other Revenue Growth
In Vitro & In Vivo Diagnostic Substances Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
AWHL's Revenue Growth Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Bio rad Laboratories Inc -0.05%$ -0.046 millions
Seer Inc -0.29%$ -0.289 millions
Dyadic International Inc -0.57%$ -0.568 millions
Teva Pharmaceutical Industries Limited-0.81%$ -0.814 millions
Aytu Biopharma Inc-0.91%$ -0.911 millions
Neuropace Inc -1.32%$ -1.323 millions
Ardent Health Inc -1.40%$ -1.400 millions
Sunshine Biopharma Inc -1.56%$ -1.557 millions
Pacific Biosciences Of California Inc -1.71%$ -1.706 millions
United Therapeutics Corporation-1.92%$ -1.916 millions
Orasure Technologies Inc-1.93%$ -1.930 millions
Pulmonx Corporation-1.93%$ -1.931 millions
Volitionrx Limited-1.97%$ -1.975 millions
Organon and Co -2.26%$ -2.258 millions
Airsculpt Technologies Inc -2.53%$ -2.527 millions
Charles River Laboratories International inc -2.72%$ -2.718 millions
Perrigo Company Plc-3.17%$ -3.171 millions
Zai Lab Limited-3.33%$ -3.333 millions
Vanda Pharmaceuticals Inc -3.92%$ -3.919 millions
Teladoc Health Inc -3.95%$ -3.952 millions
Dentsply Sirona Inc -4.06%$ -4.060 millions
Sanuwave Health Inc -4.18%$ -4.181 millions
Treace Medical Concepts Inc -4.24%$ -4.244 millions
Fortrea Holdings Inc -4.52%$ -4.519 millions
Positron Corporation-6.91%$ -6.907 millions
Standard Biotools Inc -7.05%$ -7.046 millions
Inspire Medical Systems inc -7.32%$ -7.316 millions
Adapthealth Corp -7.50%$ -7.505 millions
China Pharma Holdings Inc-7.55%$ -7.548 millions
Skinhealth Systems Inc -7.68%$ -7.680 millions


About Aspira Women S Health Inc Revenue Growth Rates (AWHL), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Aspira Womens Health Inc (CIK 926617).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000926617-26-000054
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Aspira Womens Health Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.